Home > R&D > Research field > SMART cancer drug > ACD-BT / ACD-CN

ACD-BT / ACD-CN

ACD-BT and ACD-CN were targeted to colon cancer and breast cancer, respectively. CD47 binders with strong affinity for CD47, which is abnormally overexpressed on the surface of cancer cells, were selected using ribosome display technology and the selected CD47 binders were conjugated with liposome. NT, MT and CT mRNAs, which were transcribed in vitro, were loaded into CD47 binder conjugated liposome to develop ACD-BT and ACD-CN.

These drugs can induce cell cycle arrest or cell death by bypassing the specific pathway involved in the synthesis of nucleic acids in nucleus, cytoplasm and mitochondria.


Development progress : ACD-BT / ACD-CN

Development Nonclinical Clinical Item approval Sale
ACD-BT
ACD-CN
2016~2018 2018~2020 2020~2024 2024~2025 2025 ~